Vera Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vera Therapeutics, Inc. on March 9, 2026, reporting events occurring on March 5, 2026. The Company is a Delaware corporation with its principal executive offices in Brisbane, California, and its Class A common stock trades on The Nasdaq Stock Market under the symbol "VERA".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The Board of Directors appointed Christopher Hite as a new Class III Director, effective March 5, 2026. His initial term expires at the 2027 Annual Meeting of Stockholders.
Compensation and Governance Details
- Stock Option Grant: Mr. Hite received an automatic nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share.
- Vesting Schedule: The initial option grant vests monthly over a three-year period, contingent on continuous service.
- Cash Retainer: Mr. Hite will receive an annual cash retainer of $45,000, pro-rated for 2026.
- Future Grants: Commencing with the 2027 Annual Meeting, Mr. Hite is eligible for annual option grants of the lesser of 18,000 shares or a grant date fair value of $400,000. These future grants vest on the earlier of the first anniversary of the grant date or the next annual meeting.
- Indemnification: Mr. Hite will enter into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the current market price of VERA stock relative to the $38.85 exercise price of the new director option grant.
- Review the Company's Amended and Restated Non-Employee Director Compensation Policy for full terms of the grant.
- Confirm the total number of outstanding shares and potential dilution impact of the 24,937 new options.
- Check for any subsequent filings regarding Mr. Hite's background or conflicts of interest.